Suppr超能文献

干粉吸入剂制剂的物理稳定性。

Physical stability of dry powder inhaler formulations.

机构信息

Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN, USA.

Research and Development, Insmed Incorporated, Bridgewater, NJ, USA.

出版信息

Expert Opin Drug Deliv. 2020 Jan;17(1):77-96. doi: 10.1080/17425247.2020.1702643. Epub 2019 Dec 13.

Abstract

: Dry powder inhalers (DPIs) are popular for pulmonary drug delivery. Various techniques have been employed to produce inhalation drug particles and improve the delivery efficiency of DPI formulations. Physical stability of these DPI formulations is critical to ensure the delivery of a reproducible dose to the airways over the shelf-life.: This review focuses on the impact of solid-state stability on aerosolization performance of DPI drug particles manufactured by powder production approaches and particle-engineering techniques. It also highlights the different analytical tools that can be used to characterize the physical instability originating from production and storage.: A majority of the DPI literature focuses on the effects of physico-chemical properties such as size, morphology, and density on aerosolization. While little has been reported on the physical stability, particularly the stability of engineered drug particles for use in DPIs. Literature data have shown that different particle-engineering methods and storage conditions may cause physical instability of dry powders for inhalation and can significantly change the aerosol performance. A systematic examination of physical instability mechanisms in DPI formulations is necessary during formulation development in order to select the optimum formulation with satisfactory stability. In addition, the use of appropriate characterization tools is critical to detect and understand physical instability during the development of DPI formulations.

摘要

干粉吸入器(DPIs)是一种常用于肺部药物输送的装置。已经采用了各种技术来生产吸入药物颗粒并提高 DPI 制剂的输送效率。这些 DPI 制剂的物理稳定性对于确保在保质期内向气道输送可重复剂量至关重要。

本综述重点介绍了通过粉末生产方法和颗粒工程技术制造的 DPI 药物颗粒的固态稳定性对气溶胶化性能的影响。它还强调了可用于表征生产和储存过程中产生的物理不稳定性的不同分析工具。

大多数 DPI 文献都集中在物理化学性质(如大小、形态和密度)对气溶胶化的影响上。虽然很少有关于物理稳定性的报道,特别是用于 DPIs 的工程药物颗粒的稳定性。文献数据表明,不同的颗粒工程方法和储存条件可能导致用于吸入的干粉不稳定,并会显著改变气溶胶性能。在制剂开发过程中,有必要对 DPI 制剂中的物理不稳定性机制进行系统检查,以便选择具有令人满意稳定性的最佳制剂。此外,在 DPI 制剂开发过程中,使用适当的表征工具对于检测和理解物理不稳定性至关重要。

相似文献

1
Physical stability of dry powder inhaler formulations.
Expert Opin Drug Deliv. 2020 Jan;17(1):77-96. doi: 10.1080/17425247.2020.1702643. Epub 2019 Dec 13.
2
Building respirable powder architectures: utilizing polysaccharides for precise control of particle morphology for enhanced pulmonary drug delivery.
Expert Opin Drug Deliv. 2024 Jun;21(6):945-963. doi: 10.1080/17425247.2024.2376702. Epub 2024 Jul 8.
3
Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
Curr Pharm Des. 2015;21(27):3902-16. doi: 10.2174/1381612821666150820111134.
4
The role of particle properties in pharmaceutical powder inhalation formulations.
J Aerosol Med. 2002 Fall;15(3):325-30. doi: 10.1089/089426802760292672.
5
Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics.
Pharm Res. 2022 Dec;39(12):3047-3061. doi: 10.1007/s11095-022-03363-2. Epub 2022 Sep 7.
6
Engineering the right formulation for enhanced drug delivery.
Adv Drug Deliv Rev. 2022 Dec;191:114561. doi: 10.1016/j.addr.2022.114561. Epub 2022 Oct 1.
8
Initial Development of an Air-Jet Dry Powder Inhaler for Rapid Delivery of Pharmaceutical Aerosols to Infants.
J Aerosol Med Pulm Drug Deliv. 2021 Feb;34(1):57-70. doi: 10.1089/jamp.2020.1604. Epub 2020 Aug 4.
9
Developing Dry Powder Inhaler Formulations.
J Aerosol Med Pulm Drug Deliv. 2024 Apr;37(2):90-99. doi: 10.1089/jamp.2024.29109.davm.
10
Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Expert Opin Drug Deliv. 2015 Jun;12(6):947-62. doi: 10.1517/17425247.2015.977783. Epub 2014 Nov 12.

引用本文的文献

1
Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.
Pharmaceutics. 2025 Aug 20;17(8):1077. doi: 10.3390/pharmaceutics17081077.
2
Pulmonary delivery of insulin by dry powder inhaler formulations.
Iran J Basic Med Sci. 2025;28(7):873-879. doi: 10.22038/ijbms.2025.83954.18168.
3
Development of an inhalable dry powder formulation for inhibition of SARS-CoV-2.
Int J Pharm X. 2025 Jun 14;10:100346. doi: 10.1016/j.ijpx.2025.100346. eCollection 2025 Dec.
5
6
Advancing pulmonary therapy: the role of dry powder inhalation technology in lung disease management.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 5. doi: 10.1007/s00210-025-04305-6.
7
Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy.
Pharmaceutics. 2025 Apr 7;17(4):486. doi: 10.3390/pharmaceutics17040486.
8
Navigating the Development of Dry Powder for Inhalation: A CDMO Perspective.
Pharmaceuticals (Basel). 2025 Mar 19;18(3):434. doi: 10.3390/ph18030434.
9
Advanced Manufacturing Methods for High-Dose Inhalable Powders.
Pharmaceutics. 2025 Mar 12;17(3):359. doi: 10.3390/pharmaceutics17030359.
10
Particle surface coating for dry powder inhaler formulations.
Expert Opin Drug Deliv. 2025 May;22(5):711-727. doi: 10.1080/17425247.2025.2482052. Epub 2025 Mar 26.

本文引用的文献

1
Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery.
Asian J Pharm Sci. 2018 Mar;13(2):163-172. doi: 10.1016/j.ajps.2017.10.002. Epub 2017 Oct 20.
3
Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
AAPS PharmSciTech. 2019 Feb 7;20(3):103. doi: 10.1208/s12249-018-1280-0.
5
Non-invasive delivery strategies for biologics.
Nat Rev Drug Discov. 2019 Jan;18(1):19-40. doi: 10.1038/nrd.2018.183. Epub 2018 Nov 30.
6
Current and Emerging Inhaled Therapies of Repositioned Drugs.
Adv Drug Deliv Rev. 2018 Aug;133:1-4. doi: 10.1016/j.addr.2018.09.008.
8
Using two-fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation.
Int J Pharm. 2018 Dec 1;552(1-2):67-75. doi: 10.1016/j.ijpharm.2018.09.045. Epub 2018 Sep 19.
9
Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
Pharm Res. 2018 Aug 23;35(10):195. doi: 10.1007/s11095-018-2452-z.
10
Drying Technologies for the Stability and Bioavailability of Biopharmaceuticals.
Pharmaceutics. 2018 Aug 17;10(3):131. doi: 10.3390/pharmaceutics10030131.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验